Premium
Immune hemolytic anemia associated with teicoplanin
Author(s) -
Coluccio Elena,
Villa M. Antonietta,
Villa Emmanuel,
Morelati Fernanda,
Revelli Nicoletta,
Paccapelo Cinzia,
Garratty George,
Rebulla Paolo
Publication year - 2004
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/j.0041-1132.2003.00599.x
Subject(s) - teicoplanin , medicine , anemia , hemolytic anemia , immune system , gastroenterology , immunology , vancomycin , staphylococcus aureus , biology , bacteria , genetics
BACKGROUND: Several drugs can cause immune hemolytic anemia. Here a patient who developed hemolytic anemia after treatment with teicoplanin is described. CASE REPORT: Owing to a two‐vessel disease, a 68‐year‐old white man underwent coronary artery bypass grafting. He was readmitted for superficial sternal wound infection and sternal instability. Rewiring was required and worsening anemia characterized the course after the reoperation. Drugs used in the second admission were gentamycin, teicoplanin, paracetamol, and codeine. They were considered as a possible cause of drug‐induced hemolytic anemia. RESULTS: The DAT was positive for complement and IgG. Autoanti‐e was identified in the patient's undiluted serum sample. The eluate was reactive with all RBCs tested only after adding teicoplanin; when diluted 1:4, anti‐e specificity was observed in the presence of teicoplanin. CONCLUSION: To our knowledge, this is the first report of immune hemolytic anemia owing to teicoplanin.